Scientist.com Expands VERIF.i®, its Supplier Pre-assessment Program, to Cover Chemistry, Manufacturing and Controls (CMC)
15.9.2022 03:35:00 EEST | Business Wire | Press release
Scientist.com, the biopharma industry’s leading R&D marketplace, today announced the expansion of VERIF.i, the company’s supplier pre-assessment program, to include Chemistry, Manufacturing and Controls (CMC). CMC suppliers undergo an independent 3rd party pre-assessment, which can then be shared with their entire customer base.
“On-site lab assessments are expensive, time-consuming and labor intensive. VERIF.i alleviates this by enabling an independent 3rd party to confirm that a supplier meets a customer’s research and regulatory requirements,” stated Matt McLoughlin, Sr. VP of Categories & Compliance at Scientist.com. “Pre-assessments help customers speed up supplier selection and purchase highly technical services with more confidence and less risk.”
The pre-assessments performed under VERIF.i are completed with the same independence and objectivity as a study-specific audit but can be applied across multiple clients, saving suppliers time, money and resources. VERIF.i also gives suppliers of regulated research services, such as human biospecimen acquisition—and now chemistry, manufacturing and controls—the opportunity to proactively communicate their quality standards against pre-defined criteria developed with industry partners for use across the biopharma industry.
For more information on VERIF.i, visit https://www.info.scientist.com/verifi
About Scientist.com
Scientist.com’s mission is to empower and connect scientists worldwide. Our digital research platform combines sophisticated AI technology with white-glove Research Concierge® support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 100 biotechnology companies, and the US National Institutes of Health (NIH).
Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005066/en/
Contact information
Sean Preci
marketing@scientist.com
+1 858-815-9274
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian Expands Agent Trust Partner Ecosystem with Akamai to Advance Trusted AI Driven Commerce15.5.2026 16:00:00 EEST | Press release
Experian today announced that Akamai Technologies has joined its growing partner ecosystem, designed to further advance secure, trusted AI driven commerce through the Experian Agent Trust™ framework, alongside partner Skyfire supporting emerging payment innovation. As AI agents begin to search, decide, and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer directly initiated by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust is designed to address this challenge by establishing identity, accountability, and trust in agent driven interactions. “Trust, security, and performance must scale alongside the growing role of AI agents in digital commerce,” said Kathleen Peters, Chief Innovation Officer at Experian. “Agentic commerce will not scale without trust. By adding Akamai to ou
The LYCRA Company and Dukane Advance Ultrasonic Bonding for Nonwovens at INDEX™ 2615.5.2026 15:00:00 EEST | Press release
The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the personal care industry, and Dukane, a manufacturer of ultrasonic bonding technologies for the hygiene and nonwovens market, are showcasing their latest co-developed advances in ultrasonic bonding at INDEX™ 26, taking place in Geneva, Switzerland, from May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515514441/en/ Join The LYCRA Company and Dukane at INDEX™ 26 in Geneva, as they showcase their latest advances in ultrasonic bonding for nonwovens, including new LYCRA FUSION™ fiber for personal care that delivers superior snapback. Since 2014, both companies have collaborated to advance ultrasonic bonding solutions that help diaper manufacturers improve product softness, fit, and performance while reducing energy consumption, material waste, and maintenance costs. Ultrasonic bonding creates bonded channels between two layers of n
Vecima to Highlight Next-Generation 50G-PON, DOCSIS® 4.0 vCMTS, AI & Automation, and Monetizable Streaming at ANGA COM 202615.5.2026 14:45:00 EEST | Press release
Vecima Networks Inc. (TSX: VCM) will highlight its leadership in next-generation broadband at ANGA COM 2026, showcasing AI-powered network operations, cloud-native DOCSIS® 4.0 access, and scalable fiber solutions. Anchored by the Entra® vCMTS platform, Automation, and All-PON™ innovations, Vecima is enabling operators to automate operations, improve reliability, and accelerate the evolution to converged cable and fiber networks. Delivering on Next-Generation PON With Entra All-PON™, Vecima is enabling future-ready fiber networks with a straightforward migration path from today’s 10G technologies to 50G-PON, ensuring long-term scalability and investment protection. The new Entra EPS1650 All-PON Shelf supports 50G-PON, XGS-PON, 10G-EPON, GPON, and EPON services. As a follow-on to Vecima's industry-first demonstration of a single port supporting 50G ITU PON and 10G-EPON in a Remote OLT, the EPS1650 brings that same single-port investment-protection path to GPON and XGS-PON operators in a
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 14:38:00 EEST | Press release
Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of the Group on 31 March 2026 is positive at €643 million. The net financial position on 31 December 2025 was positive for €467.6 million. “The results we have presented - said Mario Rizzante, Chairman of Reply - confirm the soundness of the path we have undertaken in recen
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 14:30:00 EEST | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “At ISPOR 2026, Organon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom